Nasdaq:US$15.99 (+0.35) | HKEX:HK$24.75 (+0.65) | AIM:£2.49 (+0.01)
搜索結果
上一篇文章   |   下一篇文章
公告及新聞稿, 腫瘤學 / 免疫學 | 2007-05-23

Chi-Med completes patient enrolment on its HMPL-004 ulcerative colitis proof-of-concept; Phase II clinical trial in China